Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Fulgent Genetics
FLGT
Fulgent Genetics
Regulatory Costs And Fierce Competition Will Choke Genomic Testing
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
09 Aug 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$21.00
3.7% overvalued
intrinsic discount
09 Aug
US$21.77
Loading
1Y
-6.0%
7D
5.3%
Author's Valuation
US$21.0
3.7% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$21.0
3.7% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-163m
925m
2014
2017
2020
2023
2025
2026
2028
Revenue US$407.9m
Earnings US$22.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
10.03%
Healthcare Services revenue growth rate
0.28%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$22.28m
Earnings '28
x
35.56x
PE Ratio '28
=
US$792.50m
Market Cap '28
US$792.50m
Market Cap '28
/
31.57m
No. shares '28
=
US$25.11
Share Price '28
US$25.11
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$20.62
Fair Value '25
